Gena Wang
Stock Analyst at Barclays
(3.34)
# 1,029
Out of 5,090 analysts
238
Total ratings
45.16%
Success rate
3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $36.60 | +36.61% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $27.87 | +222.93% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $11.21 | +194.38% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $25.49 | -1.90% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $9.77 | +43.37% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.54 | +86.74% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $77.83 | -12.62% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.81 | -12.32% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $457.26 | -9.46% | 18 | Nov 4, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $10 → $9 | $5.93 | +51.90% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $7.86 | +14.58% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $464.56 | +13.44% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $81.64 | +16.36% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $53.82 | +48.66% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.83 | +65.63% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $82 | $66.71 | +22.92% | 4 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $24.51 | -30.64% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $13.10 | +182.44% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $71.53 | -13.32% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $58.85 | -4.84% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $29.01 | -27.61% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $6.87 | +351.57% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.44 | +22.95% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.43 | -65.95% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $6.78 | +268.73% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.58 | +109.79% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.25 | +71.59% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.89 | +5,525.33% | 1 | Jan 6, 2017 |
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $36.60
Upside: +36.61%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $27.87
Upside: +222.93%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $11.21
Upside: +194.38%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $25.49
Upside: -1.90%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $9.77
Upside: +43.37%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.54
Upside: +86.74%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $77.83
Upside: -12.62%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.81
Upside: -12.32%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $457.26
Upside: -9.46%
Solid Biosciences
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $5.93
Upside: +51.90%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.86
Upside: +14.58%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $464.56
Upside: +13.44%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $81.64
Upside: +16.36%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $53.82
Upside: +48.66%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.83
Upside: +65.63%
Oct 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $66.71
Upside: +22.92%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $24.51
Upside: -30.64%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $13.10
Upside: +182.44%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $71.53
Upside: -13.32%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $58.85
Upside: -4.84%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $29.01
Upside: -27.61%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $6.87
Upside: +351.57%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.44
Upside: +22.95%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.43
Upside: -65.95%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $6.78
Upside: +268.73%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.58
Upside: +109.79%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.25
Upside: +71.59%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.89
Upside: +5,525.33%